← Back to patent-cliff list
Serdexmethylphenidate
Tier C — Watch / tradeSerdexmethylphenidate
Zevra Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adrenoceptors
Indications (approved)：特发性嗜睡症, 发作性睡病
Regional status
US
Phase II
2022-12-28
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Serdexmethylphenidate?
Approved indications include: 特发性嗜睡症, 发作性睡病.
When does the Serdexmethylphenidate patent expire?
No public expiry year is available for Serdexmethylphenidate yet; this page updates once verified.
How do I get a quote for Serdexmethylphenidate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03